A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 06 Nov 2012 Results have been presented at the American Heart Association 2012 Scientific Sessions according to a Madrigal Pharmaceuticals media release. Results were also summarised in th media release.
    • 18 Jan 2012 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top